Crossbow Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Crossbow Therapeutics, Inc. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 13 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 8 are pending. Notable registered marks include CROSSBOW and CROSSBOW THERAPEUTICS. The owner is based in Cambridge, MA.
1030 Massachusetts Avenue, Suite 210
Cambridge, MA 02138
Showing of trademarks Trademarks
Trademark Classifications
Crossbow Therapeutics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Crossbow Therapeutics, Inc. have?
Crossbow Therapeutics, Inc. has 25 U.S. trademarks filed with the USPTO. Of these, 3 registered, 8 pending, 14 abandoned.
What trademark classes does Crossbow Therapeutics, Inc. file in?
Crossbow Therapeutics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Crossbow Therapeutics, Inc.'s most well-known trademarks?
Crossbow Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as CROSSBOW and CROSSBOW THERAPEUTICS. These are among 3 currently registered trademarks in the portfolio.
What is Crossbow Therapeutics, Inc.'s trademark registration success rate?
Crossbow Therapeutics, Inc. has a 18% trademark registration rate, with 3 out of 17 resolved applications resulting in successful registration. Currently, 8 applications are pending review.